Loss of S100 antigenicity in metastatic melanoma

Dara L. Aisner, Ajay Maker, Steven A. Rosenberg, David M. Berman

Research output: Contribution to journalArticle

Abstract

Melanoma is a highly malignant disease that may initially present as a poorly differentiated metastatic tumor. Therefore, the S100 immunostain, immunoreactive in 96% to 99% of melanoma, is used to evaluate poorly differentiated malignant tumors. To develop criteria for correctly diagnosing S100-negative melanomas, we studied the immunohistochemical profile of 1553 patients enrolled in ongoing National Cancer Institute clinical trials for melanoma. Seventeen patients (1%) had metastatic melanoma specimens that were negative for S100. Of the 17 S100-negative lesions, 10 (59%) were immunoreactive for both GP100 and MART-1. Of the 17 S100-negative cases, 13 had a documented primary melanoma. Twenty-four percent of the S100-negative cases had an ocular primary, whereas only 6% of all melanomas had an ocular origin. In 11 of the 17 cases with previous surgical specimens, a prior documented S100-immunoreactive specimen was identified in 9 cases (82%). The time interval for loss of S100 immunoreactivity ranged from 3 weeks to 3 years (average, 13.5 months). There was no association between S100-negative status and histological appearance or site of metastasis. We conclude that all S100-negative melanomas could be correctly identified by negative workup for carcinoma, lymphoma, and sarcoma plus (1) GP100/MART-1 immunoreactivity and/or (2) prior documentation of melanoma.

Original languageEnglish (US)
Pages (from-to)1016-1019
Number of pages4
JournalHuman Pathology
Volume36
Issue number9
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Melanoma
National Cancer Institute (U.S.)
Sarcoma
Documentation
Lymphoma
Neoplasms
Clinical Trials
Neoplasm Metastasis
Carcinoma

Keywords

  • Antigenicity
  • Diagnosis
  • Melanoma
  • S100

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Aisner, D. L., Maker, A., Rosenberg, S. A., & Berman, D. M. (2005). Loss of S100 antigenicity in metastatic melanoma. Human Pathology, 36(9), 1016-1019. https://doi.org/10.1016/j.humpath.2005.07.010

Loss of S100 antigenicity in metastatic melanoma. / Aisner, Dara L.; Maker, Ajay; Rosenberg, Steven A.; Berman, David M.

In: Human Pathology, Vol. 36, No. 9, 09.2005, p. 1016-1019.

Research output: Contribution to journalArticle

Aisner, DL, Maker, A, Rosenberg, SA & Berman, DM 2005, 'Loss of S100 antigenicity in metastatic melanoma', Human Pathology, vol. 36, no. 9, pp. 1016-1019. https://doi.org/10.1016/j.humpath.2005.07.010
Aisner DL, Maker A, Rosenberg SA, Berman DM. Loss of S100 antigenicity in metastatic melanoma. Human Pathology. 2005 Sep;36(9):1016-1019. https://doi.org/10.1016/j.humpath.2005.07.010
Aisner, Dara L. ; Maker, Ajay ; Rosenberg, Steven A. ; Berman, David M. / Loss of S100 antigenicity in metastatic melanoma. In: Human Pathology. 2005 ; Vol. 36, No. 9. pp. 1016-1019.
@article{ff13f65b723749189dbca6fd8e72bd8b,
title = "Loss of S100 antigenicity in metastatic melanoma",
abstract = "Melanoma is a highly malignant disease that may initially present as a poorly differentiated metastatic tumor. Therefore, the S100 immunostain, immunoreactive in 96{\%} to 99{\%} of melanoma, is used to evaluate poorly differentiated malignant tumors. To develop criteria for correctly diagnosing S100-negative melanomas, we studied the immunohistochemical profile of 1553 patients enrolled in ongoing National Cancer Institute clinical trials for melanoma. Seventeen patients (1{\%}) had metastatic melanoma specimens that were negative for S100. Of the 17 S100-negative lesions, 10 (59{\%}) were immunoreactive for both GP100 and MART-1. Of the 17 S100-negative cases, 13 had a documented primary melanoma. Twenty-four percent of the S100-negative cases had an ocular primary, whereas only 6{\%} of all melanomas had an ocular origin. In 11 of the 17 cases with previous surgical specimens, a prior documented S100-immunoreactive specimen was identified in 9 cases (82{\%}). The time interval for loss of S100 immunoreactivity ranged from 3 weeks to 3 years (average, 13.5 months). There was no association between S100-negative status and histological appearance or site of metastasis. We conclude that all S100-negative melanomas could be correctly identified by negative workup for carcinoma, lymphoma, and sarcoma plus (1) GP100/MART-1 immunoreactivity and/or (2) prior documentation of melanoma.",
keywords = "Antigenicity, Diagnosis, Melanoma, S100",
author = "Aisner, {Dara L.} and Ajay Maker and Rosenberg, {Steven A.} and Berman, {David M.}",
year = "2005",
month = "9",
doi = "10.1016/j.humpath.2005.07.010",
language = "English (US)",
volume = "36",
pages = "1016--1019",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Loss of S100 antigenicity in metastatic melanoma

AU - Aisner, Dara L.

AU - Maker, Ajay

AU - Rosenberg, Steven A.

AU - Berman, David M.

PY - 2005/9

Y1 - 2005/9

N2 - Melanoma is a highly malignant disease that may initially present as a poorly differentiated metastatic tumor. Therefore, the S100 immunostain, immunoreactive in 96% to 99% of melanoma, is used to evaluate poorly differentiated malignant tumors. To develop criteria for correctly diagnosing S100-negative melanomas, we studied the immunohistochemical profile of 1553 patients enrolled in ongoing National Cancer Institute clinical trials for melanoma. Seventeen patients (1%) had metastatic melanoma specimens that were negative for S100. Of the 17 S100-negative lesions, 10 (59%) were immunoreactive for both GP100 and MART-1. Of the 17 S100-negative cases, 13 had a documented primary melanoma. Twenty-four percent of the S100-negative cases had an ocular primary, whereas only 6% of all melanomas had an ocular origin. In 11 of the 17 cases with previous surgical specimens, a prior documented S100-immunoreactive specimen was identified in 9 cases (82%). The time interval for loss of S100 immunoreactivity ranged from 3 weeks to 3 years (average, 13.5 months). There was no association between S100-negative status and histological appearance or site of metastasis. We conclude that all S100-negative melanomas could be correctly identified by negative workup for carcinoma, lymphoma, and sarcoma plus (1) GP100/MART-1 immunoreactivity and/or (2) prior documentation of melanoma.

AB - Melanoma is a highly malignant disease that may initially present as a poorly differentiated metastatic tumor. Therefore, the S100 immunostain, immunoreactive in 96% to 99% of melanoma, is used to evaluate poorly differentiated malignant tumors. To develop criteria for correctly diagnosing S100-negative melanomas, we studied the immunohistochemical profile of 1553 patients enrolled in ongoing National Cancer Institute clinical trials for melanoma. Seventeen patients (1%) had metastatic melanoma specimens that were negative for S100. Of the 17 S100-negative lesions, 10 (59%) were immunoreactive for both GP100 and MART-1. Of the 17 S100-negative cases, 13 had a documented primary melanoma. Twenty-four percent of the S100-negative cases had an ocular primary, whereas only 6% of all melanomas had an ocular origin. In 11 of the 17 cases with previous surgical specimens, a prior documented S100-immunoreactive specimen was identified in 9 cases (82%). The time interval for loss of S100 immunoreactivity ranged from 3 weeks to 3 years (average, 13.5 months). There was no association between S100-negative status and histological appearance or site of metastasis. We conclude that all S100-negative melanomas could be correctly identified by negative workup for carcinoma, lymphoma, and sarcoma plus (1) GP100/MART-1 immunoreactivity and/or (2) prior documentation of melanoma.

KW - Antigenicity

KW - Diagnosis

KW - Melanoma

KW - S100

UR - http://www.scopus.com/inward/record.url?scp=24344439755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344439755&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2005.07.010

DO - 10.1016/j.humpath.2005.07.010

M3 - Article

VL - 36

SP - 1016

EP - 1019

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 9

ER -